Open AccessEfficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT
Author(s) -
Ying Jia,
Yufei Xing,
Meitian Yang
Publication year - 2021
Publication title -
journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.228
H-Index - 54
eISSN - 1687-8469
pISSN - 1687-8450
DOI - 10.1155/2021/9120265
Subject(s) - medicine , sorafenib , gastroenterology , adverse effect , liver function , stage (stratigraphy) , vascular endothelial growth factor , survival rate , vegf receptors , oncology , hepatocellular carcinoma , paleontology , biology
Objective To explore the efficacy of sorafenib combined with interventional therapy on primary liver cancer (PLC) patients and its effect on serum AFP, VEGF, and GGT.Methods 120 PLC patients admitted to our hospital from January 2016 to January 2020 were selected as the research object and divided into group A and group B according to the admission order, with 60 cases each. Interventional therapy was performed to both groups, and sorafenib was given to group A additionally to compare their treatment effect, survival, adverse reaction rate (ARR), and serum AFP, VEGF, and GGT levels.Results After treatment, group A obtained significantly higher objective remission rate (ORR) and disease control rate (DCR) ( p < 0.05), higher one-year survival rate and two-year survival rate ( p < 0.05), lower ARR of skin reactions, gastrointestinal reactions, hepatorenal reactions, and hyperbilirubinemia ( p < 0.05), and lower serum AFP, VEGF, and GGT levels ( p < 0.001).Conclusion The combination of sorafenib and interventional therapy can inhibit the growth and migration of PLC, improve the immune function, prolong the survival period of patients, and lower ARR, so it should be promoted in practice.